FDA CE Course on ‘Biosimilars’
FDA Brief: Week of Feb 15, 2016
WHAT: Continuing Education Course for health care professionals to strengthen knowledge and understanding of biosimilars and interchangeable products – which are not generic products
WHY: Growing interest in biosimilars and interchangeable products in the pharmaceutical industry
HOW: Will inform about the development process, approval pathways, and relationships between biosimilars and interchangeable products.